1. Home
  2. CYTK vs SLG Comparison

CYTK vs SLG Comparison

Compare CYTK & SLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • SLG
  • Stock Information
  • Founded
  • CYTK 1997
  • SLG 1980
  • Country
  • CYTK United States
  • SLG United States
  • Employees
  • CYTK N/A
  • SLG N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • SLG Real Estate Investment Trusts
  • Sector
  • CYTK Health Care
  • SLG Real Estate
  • Exchange
  • CYTK Nasdaq
  • SLG Nasdaq
  • Market Cap
  • CYTK 4.6B
  • SLG 4.0B
  • IPO Year
  • CYTK 2004
  • SLG 1997
  • Fundamental
  • Price
  • CYTK $35.39
  • SLG $56.88
  • Analyst Decision
  • CYTK Buy
  • SLG Hold
  • Analyst Count
  • CYTK 13
  • SLG 15
  • Target Price
  • CYTK $71.58
  • SLG $67.40
  • AVG Volume (30 Days)
  • CYTK 1.7M
  • SLG 796.5K
  • Earning Date
  • CYTK 08-07-2025
  • SLG 10-15-2025
  • Dividend Yield
  • CYTK N/A
  • SLG 5.43%
  • EPS Growth
  • CYTK N/A
  • SLG N/A
  • EPS
  • CYTK N/A
  • SLG N/A
  • Revenue
  • CYTK $85,738,000.00
  • SLG $640,547,000.00
  • Revenue This Year
  • CYTK $330.96
  • SLG N/A
  • Revenue Next Year
  • CYTK $73.41
  • SLG $1.92
  • P/E Ratio
  • CYTK N/A
  • SLG N/A
  • Revenue Growth
  • CYTK 2635.74
  • SLG N/A
  • 52 Week Low
  • CYTK $29.31
  • SLG $45.15
  • 52 Week High
  • CYTK $59.39
  • SLG $82.81
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 49.60
  • SLG 51.56
  • Support Level
  • CYTK $36.89
  • SLG $55.16
  • Resistance Level
  • CYTK $39.92
  • SLG $57.08
  • Average True Range (ATR)
  • CYTK 1.78
  • SLG 1.31
  • MACD
  • CYTK -0.06
  • SLG 0.50
  • Stochastic Oscillator
  • CYTK 54.96
  • SLG 85.88

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About SLG SL Green Realty Corp

SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.

Share on Social Networks: